ArticleToxicology reports2021
Quercetin attenuated the Benzene-induced hemato- and hepatotoxicity in mice.
Article in Toxicology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- Nanoencapsulation of ferrocene incorporated thiourea and doxorubicin for treatment of acute myeloid leukemia.BMC cancer · 2025Article
- The Benzene-induced Hepatic Cytochrome P450 2E1 Expression and Activity are Reduced by Quercetin Administration in Mice.Current pharmaceutical design · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protective effects of Quercetin (QCN) on Benzene (BNZ)-induced hemato- and hepatotoxicy were investigated. To reach this goal, 36 adult male mice were divided into 6 groups (n = 6). The control group was not exposed to BNZ, while animals in BNZ group were exposed to BNZ (30 ppm) and the animals of QCN group were received QCN (50 mg/kg, orally), the fourth, fifth and sixth groups were exposed to 30 ppm BNZ and received 10, 50 and 100 mg/kg QCN one h before the BNZ exposure, for 28 days. The day after the last exposure following anesthesia and the blood collection, the liver and femur tissues were collected. The bone marrow samples were extracted and subjected to micronucleus assay. The blood samples were processed for hematological and biochemical analyses. Histopathological examinations were performed on the liver samples. QCN reduced significantly (p < 0.05) the BNZ-elevated hepatic enzymes and ameliorated the BNZ-induced WBC and RBC reduction. The BNZ-elevated micronucleus percentage both in the bone marrow and peripheral blood was remarkably declined in the QCN-received groups. QCN improved the BNZ-induced histopathological changes and oxidative status in the liver and serum. Our results suggest that QCN could be a protective supplement to reduce the BNZ-induced hemato- and hepatotoxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.